logo

EVIDENCE • EXPERIENCE • OUTCOMES

INTELLIGENCE BYMDReviewer
Home
About
Peptides
Contact
Back
Pre-approval drug. This compound is in active clinical trials and is not yet FDA-approved. Information here is for situational awareness only and should not be used to inform prescribing decisions.
  • No Preview Available

Maridebart cafraglutide

PipelinePhase 3PeptideInvestigationalNot approved yet. Being tested in human clinical trials.
Sponsor:
Amgen
Active US trials:
13
Earliest primary completion:
Oct 6, 2025
👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

On this page

  • Synopsis

Trials

  • Clinical trials
  • About this drug

Physicians

  • Physician Buzz
Similar Products
medicine
Zepbound
medicine
Saxenda
medicine
WEGOVY
medicine
JARDIANCE
Synopsis
Generated with AlphaAI
Product:
Maridebart cafraglutide
Category:
Indication:
Mechanism:
Safety:
Dosing:
Patient:
Reviews:
No reviews yet
see more
Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (13)

NCTPhaseStatusSponsorPrimary Completion
NCT07226765Phase 3ACTIVE_NOT_RECRUITINGAmgenAug 30, 2027
NCT07684235Phase 3RECRUITINGAmgenDec 26, 2027
Status: Investigational
Tested in peopleEvidence: Tested in peopleTested in at least one proper controlled study in people, with results.
NCT06660173
Phase 2
ACTIVE_NOT_RECRUITING
Amgen
Oct 6, 2025
NCT07871409Phase 3RECRUITINGAmgenJun 16, 2027
NCT07037459Phase 3RECRUITINGAmgenJun 30, 2028
NCT07866066Phase 3RECRUITINGAmgenSep 6, 2028
NCT07225686Phase 3ACTIVE_NOT_RECRUITINGAmgenAug 20, 2027
NCT07684144Phase 3RECRUITINGAmgenDec 26, 2027
NCT07441252Phase 2ACTIVE_NOT_RECRUITINGAmgenAug 25, 2027
NCT06858839Phase 3ACTIVE_NOT_RECRUITINGAmgenJan 21, 2027
NCT06858878Phase 3ACTIVE_NOT_RECRUITINGAmgenJan 21, 2027
NCT07575399Phase 3RECRUITINGAmgenJan 3, 2028
NCT07037433Phase 3ACTIVE_NOT_RECRUITINGAmgenJun 30, 2028

About this drug

Status
Active in clinical trials
Last Refreshed
Nov 13, 2026

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on Maridebart cafraglutide and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers

There isn't any reviews posted yet. You can be the first to review the product